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Abstract
Objective: To determine whether timing of CGM initiation offering low glucose sus-
pend (LGS) affects CGM adherence in children and youth starting insulin pump
therapy.
Methods: A 5-site RCT of pump-naïve subjects (aged 5-18 years) with type 1 diabetes
(T1D) for at least 1 year compared simultaneous pump and CGM initiation offering
LGS vs standard pump therapy with CGM initiation delayed for 6 months. Primary
outcome was CGM adherence (hours per 28 days) (MiniMed™ Paradigm™ Veo™
system; CareLink Pro™ software) over 6 months after CGM initiation. Secondary
outcome HbA1c was measured centrally. Linear mixed-models and ordinary least
squares models were fitted to estimate effect of intervention, and covariates baseline
age, T1D duration, HbA1c, gender, ethnicity, hypoglycemia history, clinical site, and
association between CGM adherence and HbA1c.
Results: The trial randomized 144/152 (95%) eligible subjects. Baseline mean age
was 11.5 ± 3.3(SD) years, T1D duration 3.4 ± 3.1 years, and HbA1c 7.9 ± 0.9%. Six
months after CGM initiation, adjusted mean difference in CGM adherence was
62.4 hours per 28 days greater in the Simultaneous Group compared to Delayed
Group (P = .007). There was no difference in mean HbA1c at 6 months. However, for
each 100 hours of CGM use per 28-day period, HbA1c was 0.39% (95% CI 0.10%-
0.69%) lower. Higher CGM adherence was associated with reduced time with glu-
cose >10 mmol/L (P < .001).
Conclusion: CGM adherence was higher after 6 months when initiated at same time
as pump therapy compared to starting CGM 6 months after pump therapy. Greater
CGM adherence was associated with improved HbA1c.
For the CGM TIME Trial Study Group and the JDRF Canadian Clinical Trial Network CCTN1101
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K E YWORD S
adherence, continuous glucose monitoring, glycemic control, insulin pump therapy, site
differences
Continuous glucose monitoring (CGM) may improve glycemic control
and quality of life in individuals with type 1 diabetes. Uptake of and
adherence to CGM has been studied in adults, children, and youth
with type 1 diabetes with significant differences between these
populations.1-8 The studies are not directly comparable due to meth-
odological differences. A common finding in all age groups was the
positive correlation between proportion of time spent using CGM and
improvements in glycemic control1-8; CGM adherence was signifi-
cantly lower in children and youth than adults.1,3,4,7 Low glucose sus-
pend (LGS) feature of CGM has been demonstrated to reduce
frequency of hypoglycemia without compromising safety or glycemic
control.9,10 However, the effect of timing of CGM initiation with
option of LGS on glycemic control has not been explored in pediatrics.
We hypothesized that simultaneous initiation of CGM offering LGS
and insulin pump therapy in children and youth will be associated with
greater CGM adherence than their later initiation. Our study's objec-
tive was to determine whether timing of CGM initiation offering LGS,
simultaneously with pump initiation or 6 months later, affects CGM
adherence and/or HbA1c over the subsequent 6 months in children
and youth with type 1 diabetes. The trial was performed in 2011 to
2014, when currently used sensors were not available, CGM was not
commonly used before pump therapy, and time-in-range was not the
standard for reporting glycemic control. We feel that our findings are
still relevant and that the main results are generalizable as CGM
becomes more user-friendly each year.
1 | RESEARCH DESIGN AND METHODS
The CGM TIME Trial was a 12-month multicenter randomized con-
trolled trial. Children and youth with type 1 diabetes for at least 1 year
who were initiating insulin pump therapy were randomly assigned to
start CGM offering LGS with their pump start (Simultaneous Group)
or 6 months later (Delayed Group). Randomization was performed
centrally, stratified by study center and by age (5-12 years vs
13-18 years), using a computer-generated randomization schedule
with variable block size. Full details of the protocol have been publi-
shed.11 There were no upper or lower limits for baseline HbA1c. Par-
ticipants were required to meet provincial criteria for starting insulin
pump therapy which include duration of diabetes (≥1 year), glycemic
control (HbA1c <10%), and regular blood glucose monitoring and
clinic visits. There was no run-in period to establish participants'
acceptance and willingness to wear CGM. Informed consent, plus
assent where indicated, was required. The trial was approved by the
Institutional Ethics Boards of each participating site. CONSORT Stan-
dards for design and reporting of clinical trials were followed.
1.1 | Study intervention
Participants received the Medtronic Veo™ pump, Contour® Link BG
meter, Medtronic Enlite™ sensors (under a Health Canada Investiga-
tional Testing Authorization until fully approved by Health Canada in
April 2013), Minilink™ REAL-Time transmitter, and CareLink™ Per-
sonal software. All participants received standard diabetes care for
children and youth at their site including the same insulin formula-
tions, multidisciplinary diabetes care and education; multiple daily
injections were rarely used. Diabetes nurse educators were trained to
provide identical pump and CGM teaching to participants in the two
randomization groups.12 Pump training included two pump training
sessions, CareLink™ training, daily telephone calls for the first 10 days
after pump initiation, and a telephone education session 1 month
after pump start. CGM support was provided by four phone calls in
the first 10 days after CGM initiation, and telephone education
1 month later. Training and programming of pump and CGM settings
were standardized for all subjects, including use of saline via the pump
and insulin via injections during the first week.11,12 The only differ-
ence between randomization groups was the timing of the CGM edu-
cation sessions relative to the pump education sessions.
LGS feature was activated in second week of CGM use, and other
CGM settings were initiated in standardized and individualized step-
wise fashion developed by the Study Group.13 Participants were
instructed to upload pump and CGM data every week to CareLink™
on home computers.
1.2 | Study outcomes
The primary study outcome was CGM adherence expressed as mean
hours per 28 days for each of the six 28-day periods following initia-
tion of CGM. CGM initiation occurred at the first study visit for the
Simultaneous Group, and at the 6-month visit for the Delayed Group.
When at least 21 days of complete data were available within a given
28-day block, a projected 28 day time period was calculated: (Total
number of CGM hours in a 28-day period/Days of CGM usage in a
28-day period) × 28 days.
The main secondary outcome was HbA1c, analyzed centrally at
baseline, 6 and 12 months (Roche Diagnostics Turbidimetric Inhibition
Immunoassay, utilizing the DCCT/NGSP formula, Dynacare Laborato-
ries, Toronto, Canada). Validated questionnaires evaluating readiness
for making behavior change14 and fear of hypoglycemia15 were col-
lected for participants and their parents. A brief de novo questionnaire
at the 12 month visit assessed participants' and parents' likelihood of
continuing to use CGM.
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Adverse events were collected on severe hypoglycemia and
severe hyperglycemia. Severe hypoglycemia was defined as an event
requiring assistance from another individual to administer carbohy-
drate, glucagon or other resuscitative efforts due to altered conscious-
ness, seizure or coma. Severe hyperglycemia was defined as a
hyperglycemic event involving all of the following: serum ketones or
large/moderate urine ketones, arterial blood pH < 7.30 or venous
pH < 7.24, serum bicarbonate <14, and treatment in hospital.
1.3 | Sample size and statistical analyses
Sample size was based on the primary outcome measure CGM use in
hours per 28 days (ie, 6 time periods before the 6 month visit for the
Simultaneous Group and before the 12 month visit for the Delayed
Group). Assuming a SD of 56.4 hours (weighted average of SDs in the
15-24 and 8-14 year age groups in two pediatric studies1,2 and all-
owing for a 10% dropout rate, 64 participants per group provided
80% power with a type 1 error rate at .05 to detect a difference in
CGM adherence of 403.2 hours per 28 days which equates to 60%
adherence which was demonstrated to be a clinically important
threshold for CGM adherence in children in the landmark CGM
study.1 This sample size could also detect a difference in HbA1c of
0.5% at 6 or 12 months with a SD of 0.93 (weighted average of SDs
at 6 months from two pediatric CGM studies1,2). To increase power
for secondary outcomes of readiness for change and fear of hypogly-
cemia, sample size was set at maximum of 150.
Demographic characteristics were described by randomization
group. Categorical variables were summarized in proportions, and
continuous variables with normal distributions with mean and SD.
Comparisons between randomization groups were tested for statisti-
cal significance using Student's t test for age, duration of diabetes,
and HbA1c. Chi square or Fisher's exact test were used as appropriate
for the categorical variables of age group, gender, ethnicity, and his-
tory of severe hypoglycemia in the 12 months prior to study entry.
The Student's t test was used to examine the univariate association
between mean CGM hours and randomization groups in each of the
six 28-day time periods after CGM initiation. Fisher's exact test was
used to compare percentages of participants not using CGM and
those using CGM >60% of the time for each randomization group in
each 28-day block after CGM initiation. Chi square test was used to
compare CGM satisfaction scores between randomization groups.
Generalized linear mixed modeling examined association between
randomization group and CGM adherence over time. Covariates
included age group, gender, ethnicity (Caucasian vs non-Caucasian), his-
tory of severe hypoglycemia in the 12 months before study entry, site,
time, time2, and an interaction factor between time and randomization
group. The intercept and time (the six 28-day periods) were specified as
random effects while randomization group and its interaction with time
were specified as fixed effects. These within-participant random effects
allowed for better understanding of the variability in CGM adherence
and the correlation of CGM adherence between baseline and subse-
quent time points. Site 1 was chosen as the reference group, as its
sample size was largest. A time2 term was included to allow for non-
linearity. The estimates from the models were reported along with stan-
dard errors and 95% confidence interval.
HbA1cs within each randomization group were summarized with
mean and SD at study entry, 6 months, and 12 months. Student's t test
was used to compare the mean HbA1cs of the randomization groups
6 months after CGM initiation, as well as change in HbA1c between
study entry and 6 months after CGM initiation. Ordinary least squares
regression was used to determine the effect of various parameters on
HbA1c 6 months after CGM initiation; covariates included baseline
HbA1c, gender, age group, randomization group, ethnicity (Caucasian
vs non-Caucasian), history of severe hypoglycemia in the 12 months
before study entry, and site.
Average CGM adherence over the six time periods was used to
analyze association between CGM adherence and HbA1c 6 months
after CGM initiation and area under the curve for projected time
spent in hypoglycemia <3.9 mmol/L (70 mg/dL) and hyperglycemia
>10 mmol/L (180 mg/dL). Ordinary least squares regression was used
for both sets of analyses, with a restricted cubic spline technique
applied to allow for non-linear effect of CGM hours. HbA1c analysis
was adjusted for baseline HbA1c, age group, gender, site, ethnicity,
and history of severe hypoglycemia. The hypoglycemia and hypergly-
cemia analyses included cluster adjustment and adjustment for age
group, gender, and site.
A P-value of less than .05 was deemed statistically significant.
Statistical analysis was performed by the CHEO Research Institute
using R version 3.4.2.16
2 | RESULTS
2.1 | Study population
Three hundred and fifty-three children and youth with type 1 diabetes
were assessed for eligibility (CONSORT Flow Diagram, Supporting
Information Figure 1), which required all participants to be naïve to
pump and CGM. One hundred and fifty-two met the inclusion criteria
and 94.7% consented to participation. One hundred and forty-four
participants were randomized, with 73 allocated to Simultaneous
Group and 71 to Delayed Group. Following randomization, 139 partici-
pants started pump therapy. There were no significant differences
between groups in mean age, age category, diabetes duration, ethnic-
ity, or history of severe hypoglycemia in the 12 months before study
entry (Table 1). The Simultaneous Group had higher HbA1c at study
entry (8.05% +/− 1.01% vs 7.72% +/− 0.88%, P = .024) (Table 1).
2.2 | Association between timing of CGM initiation
and subsequent CGM adherence
Complete information on CGM adherence in the first 6 months of
CGM was available for 124 participants. CareLink™ collected incom-
plete CGM adherence information from 15 separate participants in
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37 time periods. Five patient-time period values were excluded as
there were less than 21 days of CareLink™ CGM adherence data in a
given 28 day period; for the remaining 32 time periods, “projected
CGM hours per 28 days” was calculated as described above.
Univariate analysis showed that the Simultaneous Group had con-
sistently higher CGM adherence hours in all six time periods (Table 2).
The adjusted mean difference in CGM adherence hours between ran-
domization groups was statistically significant at all time points, and
showed increasing benefit of simultaneous CGM introduction over
time. The multivariate model showed that individuals in the Simulta-
neous Group used CGM 62.4 more hours per 28-day period (P = .007),
equivalent to an extra 2.2 hours per day, when other factors were held
constant. The proportion of participants in each randomization group
who wore CGM >60% of the time (equivalent to 403.2 hours per
28-day period) decreased for both groups over time, with proportion of
participants in the Simultaneous Group greater than in the Delayed
Group in all time periods. The difference was statistically significant in
periods 3, 4, and 5. The proportion of participants not using CGM
increased over time for both randomization groups with no significant
difference between the groups. Neither age group nor gender was sig-
nificantly associated with CGM adherence.
There was an unexpected difference in CGM adherence among the
sites (Figure 1, Table 3) with a clear separation between the Simulta-
neous and Delayed groups in three of the sites, favoring Simultaneous
Group, while in the other two sites CGM adherence rapidly decreased
in both groups. The multivariate model identified the latter two sites as
having significantly lower CGM adherence compared to the reference
site, with a difference of 87.4 (P = .016) and 126.9 (P < .001) fewer
hours per 28 days (3.1 and 4.5 hours per day respectively when each
site's randomization groups were combined). There were no differences
in baseline demographics of participants in the five sites.
2.3 | Association between timing of CGM initiation
and HbA1c 6 months after CGM initiation
HbA1c was statistically different between randomization groups at
study entry (Table 1). For this reason, post hoc it was decided that the
Site 1 Site 2 Site 3 Site 4 Site 5


























F IGURE 1 Comparison of mean CGM adherence in the Simultaneous and Delayed Groups in the six 28 day periods after the introduction of
CGM, separated by (A) study site and (B) the child’s gender
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outcome measure HbA1c after 6 months of CGM use would be calcu-
lated two ways. Six months after CGM initiation, mean HbA1c in the
Simultaneous Group was 7.94% (SD 0.84%) and in the Delayed Group
it was 7.94% (SD 0.91%) (P = .68). However the change in HbA1c
between study entry and 6 months after CGM initiation was −0.12%
(SD 0.91%) for Simultaneous Group and + 0.26% (SD 0.77%) for
Delayed Group (P = .01). A multivariate analysis exploring factors
associated with HbA1c 6 months after CGM initiation identified base-
line HbA1c (P < .001) and one of the study sites (P = .023) as the only
relevant parameters. In the multivariate model, randomization group
was not significantly associated with HbA1c 6 months after CGM
initiation.
TABLE 1 Baseline Demographics of the Study Population
Patient Characteristics at Study Entry Simultaneous Group (N = 70) Delayed Group (N = 69) P-value
Age in years (mean ± SD) 11.49 (3.34) 11.47 (3.35) .963
Age category in years (N, %)
Age 5 to 12 years 42/70 (60.0) 43/69 (62.3) .779
Age 13 to 18 years 28/70 (40.0) 26/69 (37.7)
Diabetes duration in years (mean ± SD) 3.55 (3.14) 3.25 (2.95) .966
Child gender (N, %) .676
Girls 30/70 (42.9) 32/69 (46.4)
Boys 40/70 (57.1) 37/69 (53.6)
HbA1c (mean ± SD) at study entry .024
Percentage 8.05 (1.01) 7.72 (0.88)
mmol/mol 64.5 (12.5) 60.9 (13.9)
Ethnicity (N, %) .192
Caucasian 62/70 (88.6) 59/69 (85.5)
African-American 3/70 (4.3) 0
Asian or Pacific Islander 2/70 (2.9) 4/69 (5.8)
Hispanic 0 0
Other 3/70 (4.3) 6/69 (8.7)
Number of episodes of severe hypoglycemia in the
12 months prior to study entry (N,%)
7 (10) 7 (10) .485






























1 Simultaneous 70 (0) 564.0 (91.0) 62.4 22.6 18.1 to 106.7 .006 92.9 .061
Delayed 67 (1) 505.1 (143.7) 80.6
2 Simultaneous 70 (0) 502.9 (166.8) 67.5 23.6 21.1 to 113.8 .004 80.0 .455
Delayed 67 (1) 455.8 (204.6) 73.1
3 Simultaneous 69 (1) 486.3 (177.9) 72.5 26.3 20.8 to 124.2 .006 82.6 .016
Delayed 67 (1) 408.0 (221.1) 62.7
4 Simultaneous 70 (0) 463.9 (199.4) 77.5 30.3 18.1 to 137.0 .011 72.9 .017
Delayed 66 (2) 386.7 (206.4) 51.5
5 Simultaneous 70 (0) 432.9 (212.1) 82.5 35.1 13.7 to 151.4 .019 70.0 .035
Delayed 65 (3) 355.4 (242.6) 50.8
6 Simultaneous 70 (0) 407.9 (224.1) 87.6 40.4 8.3 to 166.9 .031 65.7 .113
Delayed 65 (3) 340.2 (239.4) 50.8
a60% CGM use is equivalent to 403.2 hours per 28 days.
bExpressed in hours per 28 days; the adjusted mean hours was higher in the Simultaneous Group at all time points.
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2.4 | Exploratory analyses
A significant negative association was found between average CGM
adherence hours and HbA1c 6 months after CGM initiation (Figure 2,
Supporting Information Table 1), such that every additional 100 hours
of CGM use per 28-day period (3.57 hours per day) was associated
with a 0.38% (95% confidence interval 0.09-0.68%) reduction in
HbA1c (P = .013).




(hours per 28 days) t P-value
Randomization Group (Simultaneous) 62.4 22.6 17.8 to 107.1 2.8 .007
Age Group13-17 16.2 23.2 −29.8 to 62.2 0.7 .487
Gender (female) 39.8 23.1 −5.8 to 85.4 1.7 .086
Site 2 −69.7 33.4 −135.9 to −3.6 −2.1 .039
Site 3 −52.0 34.3 −119.9 to 15.9 −1.5 .132
Site 4 −87.4 35.7 −158.1 to −16.7 −2.5 .016
Site 5 −126.9 33.6 −193.3 to −60.4 −3.8 <.001
Time −52.9 8.1 −68.7 to −37.1 −6.6 <.001
Time2 3.5 1.3 1.0 to 6.1 2.7 .007
Simultaneous group × time 0.6 34.8 −68.2 to 69.5 0.0 .411
Ethnicity (Caucasian) 38.0 37.7 −36.6 to 112.5 1.0 .315
Episode of severe hypoglycemia in the 12 months prior to
study entry



















F IGURE 2 Association between CGM adherence hours per 28 days and HbA1C 6 months after CGM initiation as determined by ordinary
least squares regression
284 LAWSON ET AL.
A model investigating estimated area under the curve for propor-
tion of time spent with blood glucose <3.9 mmol/L (70 mg/dL) and
average CGM adherence hours did not find a significant association
between these two factors (P = .192), however study site was found
to be associated with estimated time spent in hypoglycemia
(P < .001). In contrast, increasing CGM use was significantly associ-
ated with reduction in time spent with blood glucose >10 mmol/L
(180 mg/dL) (P < .001). Study site was also associated with time spent
in hyperglycemia (P = .003) (Supporting Information Figure 2A,B).
2.5 | Adverse events
There were four episodes of severe hypoglycemia in each randomiza-
tion group during the 12 months of the study. In the Simultaneous
group, three of the four participants were using CGM with LGS active
at the time of the event. In the Delayed Group, two of the four partic-
ipants were using CGM with LGS active at the time of the event.
There were three episodes of DKA during the trial, and all occurred in
participants in the Delayed Group who were not using CGM at
the time.
2.6 | Patient satisfaction
At the conclusion of the trial, participants were asked to rate on a
5-point Likert scale how likely they would be to continue CGM.
44.4% of children/youth, 64.0% of mothers, and 65.5% of fathers
reported they would be “likely” or “very likely” to continue CGM.
There was no statistical difference in response distribution between
randomization groups.
3 | DISCUSSION
Our main conclusions were the following: first, that simultaneous initi-
ation of CGM with the option of LGS and insulin pump therapy was
associated with greater CGM adherence in the first 6 months com-
pared to initiation of CGM with option of LGS 6 months after starting
pump therapy (though this effect varied between sites); second, that
there was no significant difference in mean HbA1c 6 months after
CGM initiation although there was a significant difference in change
in HbA1c favoring the Simultaneous Group; and third, that greater
CGM adherence was associated with improved glycemic control at
6 months.
Our first conclusion is consistent with our hypothesis that simul-
taneous initiation of CGM and pump therapy would result in improved
CGM adherence. This hypothesis was based on the idea that simulta-
neous initiation would capitalize on readiness for change that individ-
uals in the process of changing their insulin delivery method would be
experiencing, while also reinforcing the concept that CGM is an inte-
gral part of pump therapy, as opposed to an optional addition. The
readiness for change hypothesis was examined by having all parents
and youth who were age 10 years and older complete the validated
SOCRATES questionnaire14 at baseline and 6 months later, and while
motivational stage was associated with glycemic control at trial entry,
it did not predict future diabetes-related behavior or HbA1c. Our
CGM adherence results are supported by Moreno-Fernandez et al's
26 week study17 involving 22 adults with type 1 diabetes about to
start pump therapy. Their participants were randomized to start CGM
3 weeks before starting pump therapy or 3 weeks after. Those who
started CGM before pump therapy had 84.6% CGM adherence com-
pared with 64.0% in those who started pump therapy first. Hypogly-
cemia, measured by CGM and by number of hypoglycemia events,
was significantly lower in their early CGM group. Their study did not
include the LGS option. It is surprising that in our study, CGM that
offered LGS did not have an effect on frequency of hypoglycemia
measured as AUC < 4 mmol/L or on frequency of severe hypoglyce-
mia, with four episodes over 6 months in each group. This was lower
than in the 12 months before the study, during which seven partici-
pants in each group reported an episode of severe hypoglycemia. The
lack of effect on frequency or severity of hypoglycemia is likely
because it was designed to be a pragmatic study with no minimum
A1c for participation and therefore many participants entered the
study with excellent control. As a result, there was a floor effect,
which would have impacted results in our study. CGM offering LGS
was found to be associated with lower fear of hypoglycemia in partici-
pants and their parents as measured by the Hypoglycemia Fear
Scare.18
CGM adherence is known to be lower in children and youth com-
pared to adults with type 1 diabetes.1,3,4,7 Mean CGM adherence in
our study was similar to what has been reported previously in pediat-
ric diabetes.1-3 There was a trend toward greater CGM adherence in
female participants, which did not reach statistical significance
(P = .086). In our trial, at the 6-month mark, 65.7% of participants in
the Simultaneous group and 50.8% of those in the Delayed group
were using CGM over 60% of the time. This represented a significant
decrease in adherence compared to the first month of CGM use for
both randomization groups, though the decrease was less in the
Simultaneous group. Previous studies have examined barriers to CGM
adherence in adolescents, which include body image, loss of freedom,
pain, annoyance with alarms, and data overload.19,20 The addition of
CGM to the diabetes regimen may affect the child–parent relation-
ship, especially if parents and children have different goals and expec-
tations19 and may add to the already-significant burden of managing
diabetes on a day-to-day basis. It makes sense that introducing CGM
and pump therapy together might decrease the perceived burden of
CGM by combining it with the increased flexibility that pump therapy
offers to youth.
One of the strengths of the CGM TIME Trial is the structured,
stepwise, and specific CGM teaching approach, most of which we
described in detail in a separate publication.13 Even with this degree
of standardization, differences in personal approach and institutional
culture introduce variability, and this may have contributed to the
unexpected difference in intervention effect between study sites. The
trial was conducted when sensor technology was relatively new.
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Three of the sites had considerable experience with the Medtronic
Pump CGM System prior to the study. In contrast, before the study,
the other two sites had rarely or never taught and supported children
and youth on the Medtronic Pump CGM System. An Australian
study,21 piloted with two diabetes educators in Canada, examined dia-
betes educators' perceptions of factors that support and limit the use
of diabetes technologies such as CGM in people with T1D, and found,
while care was well intentioned, it was often not delivered with
appropriate technology expertise. This demonstrates the importance
of comprehensive training and support for clinic staff on diabetes
technologies that are new to them so that they can teach and fully
support patients and families on how to effectively use emerging
technologies.
Our second and third conclusions relate to effect of CGM on
HbA1c and the association between CGM adherence and glycemic
control. A 2011 meta-analysis6 suggested that for every 1 day per
week of CGM use, HbA1c decreases by 0.15%, with greater effect
seen in individuals with a higher HbA1c before starting CGM. We did
not find an effect on mean HbA1c at 6 months in either group; how-
ever, there was a significant difference between the groups in change
in HbA1c 6 months after CGM initiation. While individuals in the
Delayed Group had a small increase in HbA1c 6 months after CGM ini-
tiation, those in the Simultaneous Group had a small decrease. This may
be related to the often-observed phenomenon of a temporary drop in
HbA1c immediately after pump initiation, with a gradual increase over
time.20 In the Simultaneous Group, we could not separate the pump
effect from the CGM effect. Mean HbA1c at study entry was 8.05% in
the Simultaneous Group and 7.72% in the Delayed Group, representing
average control for children and youth, although above recommended
levels. The level of metabolic control at study entry likely contributed
to the lack of effect of CGM on mean HbA1c. In agreement with the
meta-analysis, we found that improvements in HbA1c were associated
with greater CGM adherence. Area under the curve for both hypoglyce-
mia (<3.9 mmol/L; 70 mg/dL) and hyperglycemia (>10 mmol/L;
180 mg/dL) is frequently reported in pediatric CGM studies. In our
study, greater adherence with CGM was associated with less hypergly-
cemia, a finding also reported in the SWITCH trial.3
The main limitation of our study is the delay in publication and
our inability to calculate time-in-range which in 2019 was rec-
ommended as a clinical target and outcome measurement that com-
plements HbA1c.23 Our trial used the Enlite™ sensor and Minimed™
Paradigm™ Veo™ pump, however, we feel that issues of CGM adher-
ence are likely generalizable among different CGM brands. The issues
of data overload, alarm fatigue, and the interplay with normal child
development and youth-parent relationships are ubiquitous.19 Adjust-
ment for multiple comparisons was not done as generalized linear
mixed modeling and ordinary least squares regression included multi-
ple covariates including baseline A1c, gender and age.
Strengths of our study include good internal validity, as the only
difference between groups was the timing of CGM initiation. There
was also good external validity due to the intention-to-treat analysis,
the low dropout rate, and minimal preselection of participants. There
was no run-in period to choose participants who were most likely to
succeed, unlike many previous CGM trials.1,3,5 The between-site dif-
ferences reflect the reality of managing a condition that depends on
the interaction of patients and the medical team.
In conclusion, our data suggest that initiating CGM with the
option of LGS in a pediatric population with type 1 diabetes at the
time of pump initiation is preferable to afterwards. CGM devices that
have been approved since our study was completed are being started
successfully before pump therapy and with multiple daily injections.24
Our results, as well as those from previous studies, notably the STAR3
trial,2 demonstrate that young patients (and their parents) are able to
adapt to both new technologies at once, and that the simultaneous
use of both devices has the potential to improve diabetes
management.
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